Clinical-stage, LSE-listed, developing DNA and mRNA-based gene therapies targeting age related diseases and longevity. Lead programs target dog health and human health including MASH, Sarcopemia and Glaucoma.
Portfolio
Investments and advisory engagements.
A selected record of direct investments, strategic and financial advisory positions, and governance roles.
Current
AI-powered platform developing next-generation therapeutics for severe allergy and mast cell related diseases, through precision immunotherapy and novel biologic approaches. Developed first-in-class mRNA-tLNP based in vivo CAR-T cell therapy specifically targeting Mast cells.
Clinical stage venture, spun out of the University of Florida, developing mRNA based personalised cancer immunotherapeutics and combination therapies leveraging AI guided novel tumour antigen discovery platforms.
Stealth Gene Editing Company
Cambridge MA based early-stage venture developing next-generation mRNA-tLNP in vivo gene editing therapeutics.
Past
Arch Venture backed mRNA therapeutics platform. Developed revolutionary microfluidics based "RNA on biochip" manufacturing platform. Advised on business development and financing strategy through company acquisition by Medici Therapeutics in December 2025.
Truffle Capital backed, clinical-stage venture (formerly Diaccurate) developing first-in-class precision oncology therapeutics, including a dual node PAM inhibitor and a KIF20A inhibitor across multiple cancer indications. Advised on business development and financing strategy.